HomeQuestion

Is there role of HER2 directed therapy in adjuvant treatment of colon adenocarcinoma for tumors that are HER2 3+ by IHC?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

Would you consider using enasidenib off-label for a cholangiocarcinoma with IDH2 mutation that has progressed on numerous lines of standard of therapy?

In a patient with unresectable HCC who developed immune-related colitis with the first dose of tremelimumab/durvalumab, would you consider continuing durvalumab alone after resolution of the colitis with steroid treatment?

How would you approach first-line treatment for a patient with metastatic colon cancer who develops an anaphylactic reaction to cetuximab with FOLFOX/cetuximab/encorafenib?

Would you offer any adjuvant therapy for a young patient with anal cancer s/p definitive chemoradiation and R0 resection with significant residual disease?

Would you include chemotherapy and/or bevacizumab with immunotherapy in patients with MSI-H/dMMR metastatic colon cancer based off the COMMIT trial results?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.